We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+1.53%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$64.8B
AUM Growth
-$1.23B
(-1.9%)
Cap. Flow
+$395M
Cap. Flow
% of AUM
0.61%
Top 10 Holdings %
Top 10 Hldgs %
28.4%
Holding
1,116
New
212
Increased
277
Reduced
389
Closed
160
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$330M |
| 2 |
CTRA
Coterra Energy
CTRA
|
+$214M |
| 3 |
Boston Scientific
BSX
|
+$204M |
| 4 |
RB Global
RBA
|
+$183M |
| 5 |
Chevron
CVX
|
+$131M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$190M |
| 2 |
Royalty Pharma
RPRX
|
+$187M |
| 3 |
Dover
DOV
|
+$178M |
| 4 |
Boeing
BA
|
+$168M |
| 5 |
Devon Energy
DVN
|
+$155M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.24% |
| 2 | Healthcare | 15.45% |
| 3 | Financials | 12.46% |
| 4 | Industrials | 9.23% |
| 5 | Communication Services | 8.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
726
Lifestance Health
LFST
$4.16B
| $8.07M | 0.01% |
1,266,985
| – | – |
|
727
HP
HPQ
$23.5B
| $8.05M | 0.01% |
419,036
-74,800
| -15% | -$1.45M |
|
728
PTC
PTC
$13.7B
| $8.01M | 0.01% |
56,200
-16,900
| -23% | -$2.67M |
|
729
Symbotic
SYM
$5.11B
| $8M | 0.01% |
+150,440
| New | +$8.61M |
|
|
TWO
730
Two Harbors Investment
TWO
$1.27B
| $7.99M | 0.01% |
700,000
+450,000
| +180% | +$5.04M |
|
731
Palisade Bio
PALI
$339M
| $7.88M | 0.01% |
4,500,000
| – | – |
|
732
Fastenal
FAST
$54B
| $7.74M | 0.01% |
166,792
-19,800
| -11% | -$888K |
|
733
Wynn Resorts
WYNN
$10.1B
| $7.65M | 0.01% |
75,300
-900
| -1% | -$98.5K |
|
734
American International
AIG
$41.9B
| $7.57M | 0.01% |
100,638
-386,500
| -79% | -$29.6M |
|
|
NSA
735
DELISTED
National Storage Affiliates Trust
NSA
| $7.55M | 0.01% |
+200,000
| New | +$6.76M |
|
|
WAY
736
Waystar Holding Corp
WAY
$4.32B
| $7.35M | 0.01% |
305,050
-800,404
| -72% | -$21.2M |
|
737
LKQ Corp
LKQ
$6.58B
| $7.34M | 0.01% |
+250,010
| New | +$8.02M |
|
|
NP
738
Neptune Insurance Holdings
NP
$4.15B
| $7.26M | 0.01% |
300,000
-14,981
| -5% | -$347K |
|
739
Wave Life Sciences
WVE
$1.12B
| $7.25M | 0.01% |
1,000,000
-8,786,061
| -90% | -$114M |
|
740
Otis Worldwide
OTIS
$27.4B
| $7.22M | 0.01% |
+93,615
| New | +$8.19M |
|
741
Celanese
CE
$5.09B
| $7.1M | 0.01% |
+108,000
| New | +$5.64M |
|
|
SUNC
742
SunocoCorp LLC
SUNC
$3.93B
| $6.88M | 0.01% |
111,532
-15,000
| -12% | -$852K |
|
|
CTLP
743
DELISTED
Cantaloupe
CTLP
| $6.76M | 0.01% |
625,661
-180,298
| -22% | -$1.91M |
|
744
Conagra Brands
CAG
$7.07B
| $6.71M | 0.01% |
426,845
+104,000
| +32% | +$1.84M |
|
|
FPS
745
Forgent Power Solutions
FPS
$9.33B
| $6.66M | 0.01% |
+227,427
| New | +$7.57M |
|
746
Vulcan Materials
VMC
$36.3B
| $6.62M | 0.01% |
24,308
+12,010
| +98% | +$3.53M |
|
|
AEVA
747
Aeva Technologies
AEVA
$1.02B
| $6.58M | 0.01% |
500,000
| – | – |
|
748
Camden Property Trust
CPT
$11.3B
| $6.57M | 0.01% |
67,300
-13,800
| -17% | -$1.46M |
|
|
NVMI
749
Nova
NVMI
$13.9B
| $6.51M | 0.01% |
15,000
-50,000
| -77% | -$22M |
|
750
Molson Coors Class B
TAP
$7.68B
| $6.5M | 0.01% |
151,036
-1,800
| -1% | -$85.5K |
|
Similar funds
Adage Capital Partners's Q1 2026 Portfolio in Review
As of Q1 2026, Adage Capital Partners held 1,116 positions worth $64.8B, down 1.9% from $66.1B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Adage Capital Partners's Q1 2026 filing shows 212 new, 277 increased, 389 reduced and 160 closed positions. Its largest new stake was Takeda Pharmaceutical: 6,424,984 shares worth $119M. The largest sale was Avidity Biosciences, an estimated $190M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 29% a quarter earlier, followed by Healthcare and Financials.
- Adage Capital Partners's largest Q1 2026 buy was Takeda Pharmaceutical: 6,424,984 shares worth $119M.
- Adage Capital Partners added most to Revolution Medicines in Q1 2026, an estimated $330M increase.
- Adage Capital Partners's biggest Q1 2026 reduction was Royalty Pharma, cutting an estimated $187M.
- Adage Capital Partners fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
- Adage Capital Partners's ten largest holdings make up 28% of its $64.8B portfolio in Q1 2026.
- Adage Capital Partners opened 212 new positions and closed 160 in Q1 2026.
- Adage Capital Partners's portfolio value fell 1.9% quarter-over-quarter to $64.8B.
Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.